Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.

abstract：PURPOSE:This phase II study was performed to evaluate the efficacy and safety of cisplatin/pemetrexed combined with 15 mg/kg of bevacizumab followed by pemetrexed/bevacizumab maintenance therapy as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to epidermal growth factor rec...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukushima T,Wakatsuki Y,Kobayashi T,Sonehara K,Tateishi K,Yamamoto M,Masubuchi T,Yoshiike F,Hirai K,Hachiya T,Koizumi T

更新日期：2018-06-01 00:00:00

abstract：:Some of 66 patients with head and neck tumors were treated with high-dose methotrexate monochemotherapy. The use of a prospective mathematical model with pharmacokinetic surveillance proved to be reliable, practical, and useful. By this means chemotherapy could be individualized, with a resultant marked reduction in t...

journal_title：Cancer chemotherapy and pharmacology

authors： Favre R,Monjanel S,Alfonsi M,Pradoura JP,Bagarry-Liegey D,Clement S,Imbert AM,Lena N,Colonna d'Istria J,Cano JP,Carcassonne Y

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94. METHODS:Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 cours...

journal_title：Cancer chemotherapy and pharmacology

authors： Cohen IJ,Toledano H,Stein J,Kollender Y,Fenig E,Konen O,Bar-Sever Z,Issakov J,Feinmesser M,Avigad S,Ash S

更新日期：2019-05-01 00:00:00

abstract：PURPOSE:The combination of docetaxel, cisplatin and 5-fluorouracil (DCF) is a newly developed chemotherapy regimen for esophageal cancer. Severe neutropenia is dose-limiting toxicity of docetaxel and it is well known to be frequently occurred during DCF chemotherapy. This study aimed to investigate the relationship bet...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura H,Tsuji D,Demachi K,Mochizuki N,Matsuzawa H,Yano T,Daiko H,Fujii S,Kojima T,Itoh K,Kawasaki T

更新日期：2020-08-01 00:00:00

abstract：:The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of mitomycin C (MMC), used at different concentrations, in inhibiting the growth of human gastric adenocarcinoma (AGS) cells. Combined verapamil and hyperthermia treatment resulted in a significan...

journal_title：Cancer chemotherapy and pharmacology

authors： Shchepotin IB,Buras RR,Nauta RJ,Shabahang M,Evans SR

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Ifosfamide is becoming an important clinical anticancer drug. Meaningful pharmacology studies require quantification of its activated and active metabolites, 4-hydroxyifosfamide (HOIfos) and isophosphoramide mustard (IPM), respectively. METHODS:Current methodology for quantifying the unstable HOIfos in biologi...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,McCain DM,Tendian SW,Tillery KH

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Oxaliplatin (OHP) in combination with 5-fluorouracil/leucovorin (FOLFOX) is clinically used as frontline therapy in patients with advanced colorectal carcinoma (CRC), with response rates ranging from 46 to 71%. This combination is now considered a standard treatment for metastatic CRC and also in the post-opera...

journal_title：Cancer chemotherapy and pharmacology

authors： Garg MB,Ackland SP

更新日期：2011-04-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00

abstract：:A highly sensitive enzyme-linked immunosorbent assay (ELISA) for etoposide (EP) was developed, which is capable of accurately measuring as little as 40 pg EP/ml. Anti-EP sera were obtained by immunizing rabbits with EP conjugated with mercaptosuccinyl bovine serum albumin (MS.BSA) using N-[beta-(4-diazophenyl)ethyl]ma...

journal_title：Cancer chemotherapy and pharmacology

authors： Saita T,Fujiwara K,Kitagawa T,Mori M,Takata K

更新日期：1990-01-01 00:00:00

abstract：:We investigated the antitumor activity of cis-diammine[1,1-cyclobutanedicarboxylato]platinum(II) (CBDCA, JM8) and cis-dichloro-trans-dihydroxybis(isopropylammine)platinum(IV) (CHIP, JM9) for the cis-DDP-sensitive and -resistant IgM immunocytoma in the LOU/M Wsl rat. The optimal dose for the antitumor effect of cis-dia...

journal_title：Cancer chemotherapy and pharmacology

authors： Steerenberg PA,Vendrik CP,de Jong WH,de Groot G,Fichtinger-Schepman AM,Scheefhals AP,Schornagel JH

更新日期：1988-01-01 00:00:00

abstract：:Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffet E,Khelfaoui F,Philip I,Biron P,Brunat-Mentigny M,Philip T

更新日期：1997-01-01 00:00:00

abstract：:The value of estrogen receptor (ER) status in the prediction of tumor response to combination chemotherapy was retrospectively analyzed in breast cancer patients selected for prospective controlled trials of chemotherapy (85 with advanced disease and 256 with operable tumors). All patients were previously untreated wi...

journal_title：Cancer chemotherapy and pharmacology

authors： Bonadonna G,Valagussa P,Tancini G,Di Fronzo G

更新日期：1980-01-01 00:00:00

abstract：:For years, MDA-MB-435 cells have been widely but erroneously used as breast cancer cells with aggressive behaviour. Recent data show that they are in fact melanoma cells. However, many scientists are still unaware of this "new" identity. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lacroix M

更新日期：2009-02-01 00:00:00

abstract：PURPOSE:To investigate whether coadministration of vindesine is a risk factor for acute kidney injury caused by high-dose methotrexate in patients with hematologic malignancies and identify its mechanism. METHODS:A retrospective analysis was conducted on 211 cycles of HD-MTX therapy in 178 patients with hematological ...

journal_title：Cancer chemotherapy and pharmacology

authors： Huang C,Xia F,Xue L,Liu L,Bian Y,Jin Z,Miao L

更新日期：2020-02-01 00:00:00

abstract：PURPOSE:Although anthracycline is a key agent in breast cancer treatment, its use is associated with the risk of cardiotoxicity. Recently, the value of combination therapy with docetaxel and cyclophosphamide was reported. Because the characteristics of paclitaxel differ on weekly versus tri-weekly administration, such ...

journal_title：Cancer chemotherapy and pharmacology

authors： Masuda N,Nakayama T,Yamamura J,Kamigaki S,Taguchi T,Hatta M,Sakamoto J

更新日期：2010-05-01 00:00:00

abstract：:Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor model. The activity of lanreotide may be due to a reduction in the levels of growth factors such as insulin grow...

journal_title：Cancer chemotherapy and pharmacology

authors： Maulard C,Richaud P,Droz JP,Jessueld D,Dufour-Esquerré F,Housset M

更新日期：1995-01-01 00:00:00

abstract：:BS compounds, a series of new dihydropyridines, successfully overcame multidrug resistance in P388/ADR cells in vitro. These agents synergistically potentiated the cytotoxicity of Adriamycin to P388/ADR cells at a concentration of 1-2 microM, whereas they showed hardly any synergistic effect in the parental cell line ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yoshinari T,Iwasawa Y,Miura K,Takahashi IS,Fukuroda T,Suzuki K,Okura A

更新日期：1989-01-01 00:00:00

abstract：:KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were com...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi E,Okabe M,Kono M,Arai H,Kasai M,Gomi K,Lee JH,Inaba M,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：PURPOSE:Fruquintinib (HMPL-013) is a novel, potent, and highly selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors (1, 2 and 3). This study was conducted to investigate the metabolism, excretion, and pharmacokinetics of HMPL-013 after a single oral dose to healthy Chinese men....

journal_title：Cancer chemotherapy and pharmacology

authors： Zhou S,Shao F,Xu Z,Wang L,Jin K,Xie L,Chen J,Liu Y,Zhang H,Ou N

更新日期：2017-09-01 00:00:00

abstract：PURPOSE:Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarker...

journal_title：Cancer chemotherapy and pharmacology

authors： Shinke H,Masuda S,Togashi Y,Ikemi Y,Ozawa A,Sato T,Kim YH,Mishima M,Ichimura T,Bonventre JV,Matsubara K

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Bevacizumab is approved for various cancers. This analysis aimed to comprehensively evaluate bevacizumab pharmacokinetics and the influence of patient variables on bevacizumab pharmacokinetics. METHODS:Rich and sparse bevacizumab serum concentrations were collected from Phase I through IV studies in early a...

journal_title：Cancer chemotherapy and pharmacology

authors： Han K,Peyret T,Marchand M,Quartino A,Gosselin NH,Girish S,Allison DE,Jin J

更新日期：2016-08-01 00:00:00

abstract：:Selective protection of the normal host tissues from the toxic effects of anticancer agents would allow the use of higher, probably more effective, doses of the drugs. It has been demonstrated that delayed high-dose uridine administration after 5-fluorouracil decreases the extent of myelosuppression and causes faster ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kralovanszky J,Prajda N,Kerpel-Fronius S,Bagrij T,Kiss E,Peters GJ

更新日期：1993-01-01 00:00:00

abstract：:We studied bioavailability, treatment schedule dependence, and therapeutic efficacy of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine), against murine tumors and human tumor xenografts. The rate of its intestinal absorption was about 50%, and it was immediately metabolized to its parent comp...

journal_title：Cancer chemotherapy and pharmacology

authors： Narita T,Koide Y,Yaguchi S,Kimura S,Izumisawa Y,Takase M,Inaba M,Tsukagoshi S

更新日期：1991-01-01 00:00:00

abstract：BACKGROUND:Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been identified. Our aim was to investigate the association between ...

journal_title：Cancer chemotherapy and pharmacology

authors： Crucitta S,Del Re M,Paolieri F,Bloise F,Sbrana A,Sammarco E,Mercinelli C,Cucchiara F,Fontanelli L,Galli L,Danesi R

更新日期：2020-10-01 00:00:00

abstract：PURPOSE:Recently, based on results of the PACIFIC trial, durvalumab after chemoradiotherapy (CRT) became the standard therapy for unresectable stage III non-small cell lung cancer (NSCLC). However, in the PACIFIC trial, patients were recruited and randomized after CRT, and certain patients were considered ineligible af...

journal_title：Cancer chemotherapy and pharmacology

authors： Hosoya K,Fujimoto D,Kawachi H,Sato Y,Kogo M,Nagata K,Nakagawa A,Tachikawa R,Hiraoka S,Kokubo M,Tomii K

更新日期：2019-08-01 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：:The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Krivit W,Chilcote R,Pyesmany A,Anderson J,Hammond D

更新日期：1979-01-01 00:00:00

abstract：PURPOSE:This study was performed to determine the maximum tolerated dose (MTD) and toxicity of vinorelbine when used in combination with doxorubicin and methotrexate with leucovorin rescue in women with metastatic breast cancer. METHODS:Enrolled in the study were 23 women with metastatic breast cancer who had not rece...

journal_title：Cancer chemotherapy and pharmacology

authors： Subramanyan S,Abeloff MD,Bond SE,Davidson NE,Fetting JH,Gordon GB,Kennedy MJ

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS:Patients received ramucir...

journal_title：Cancer chemotherapy and pharmacology

authors： Smit EF,Garon EB,Reck M,Cappuzzo F,Bidoli P,Cohen RB,Gao L,O'Brien LM,Lee P,Zimmermann A,Ferry DR,Melemed AS,Pérol M

更新日期：2018-07-01 00:00:00

abstract：:To evaluate toxicity and efficacy of chemotherapy in elderly patients (> or = 65 years of age) with advanced colorectal cancer, data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed comparing the results of treatment in those 65 years of age or old...

journal_title：Cancer chemotherapy and pharmacology

authors： Chiara S,Nobile MT,Vincenti M,Lionetto R,Gozza A,Barzacchi MC,Sanguineti O,Repetto L,Rosso R

更新日期：1998-01-01 00:00:00